Early Treatment of Systemic Onset JIA with Anakinra Restores The Il-18 Response

0

First line treatment with anakinra (an interleukin-1 (IL-1) receptor antagonist), results in a “good” clinical response (ACRp90) in patients newly diagnosed with systemic onset juvenile idiopathic arthritis (SoJIA), and restores the deficient IL-18 response of natural killer (NK) cells*, according to a new study presented June 12 at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.


Read

Immunotherapy for Cancer with Designer T-cells and Nk Cells

7

Scientists have created a novel, hybrid immune cell that combines two kinds of immune cells—T cells and natural killer (NK) cells, which can destroy cancer cells.


Read

Understanding The Immune System

19

Immune system is the foundation for good health.


Read